Team members
The Company has assembled seasoned professionals, each with decades of experience in their respective fields.
Board of Directors
Daniel A. Rüfenacht
MD, Prof. of Neuroradiology, focus Interventional Neuroradiology, SwissNeuroRadiologyInstitute and Klinik Hirslanden. Clinical experience and academic career in Switzerland, France, UK and US. Involved in translational efforts towards novel technologies to understand, asses, monitor and treat neurovascular diseases in collaboration with CABMM.UZH.ch. 250+ publications, involved in 23 national and 4 European research grants. Co-founder and chair of the SwissNeuroFoundation.org.
Patrick Scherrer
Former CEO at Widmann Associates (2004-2013), a corporate advisory firm dedicated to venture capital funds (Vinci Capital/Renaissance, Wellington Partners) and corporations. Patrick developed several investments in the technology and life-sciences sectors, including Actelion, Axovan, Endoart, immatics, Sensimed, Symetis, Evolva and Anergis among others.
Robert Bishop
Dr h.c., M.Sc. in Mathematical Sciences. Former Chairman and CEO of Silicon Graphics. Founder and President of the International Centre for Earth Simulation in Geneva.
Yves Claude Aubert
MBA IMD, Certified Financial Analyst & Portfolio Manager. Pioneer in financial derivatives trading and e-banking. Former Head of Strategic Projects at BCV. Member of several Boards of Directors and Advisory Boards of financial institutions.
Hans von Känel
Ph.D. in natural sciences at ETH Zürich in 1978; post-doctoral Associate at MIT in Cambridge, Massachusetts, USA, 1979 - 1981; senior researcher at ETH Zürich 1981-2002; ordinary professor of physics at the Politecnico di Milano 2002-2007; CTO of the start-ups Epispeed 2003-2010 and PileGrowth Tech 2012-2015; 400+ scientific publications in surface & interface physics, semiconductor physics, nanotechnology and epitaxial growth; 20 patent applications.
Abed Hammoud
Doctor of Science in Biomedical/Electrical Engineering from Washington University in St Louis (1994), MBA from IMD in Lausanne (2005). A founding member of three leading medical technology companies in the US and Europe. Currently the CEO of Renishaw Mayfield SA, a leading neurosurgical robotics company.
Management
Philippe Le Corre
Civil Aerospace Engineer, INSEAD and London Business School. Philippe started his career as flight test engineer (till RAFALE A), responsible of the Hermes Space Shuttle project and detached expert towards the European Commission, representing the Aerospace Industry. He then worked for Digital Equipment Corporation, IBM and EDS where he managed high complexity projects, mainly with ERP (SAP) and PLM (Dassault Systemes), with customers like Pechiney, Renault, PSA, Alstom and Saint Gobain.
Zoltan Czigler
M.Sc. in Engineering Mathematics; MBA from INSEAD in 2000. Former CFO in several VC-funded early-stage technology-based ventures, including Kuros Biosurgery AG in Zurich, Sensimed SA in Lausanne, Anergis SA in Lausanne, ChromaCon AG in Zurich.
Manolis Choumas
Low-T bonding and Epitaxy M.Sc. Chalmers University of Technology, Former Senior Development Engineer at Microsemi Semiconductor Corp.
Jorge Neves
M.Sc. in Biomedical Engineering, University of Coimbra, Portugal; 8+ years of R&D experience in radiation detectors and electronics for particle physics and medical imaging technologies at LIP, Portugal, in collaboration with CERN and EPFL in Switzerland.
Nasser Razek
Former Operation Development Manager at EVG. Diplom in Experimental and Nuclear Physics at the University of Cairo, Egypt (1993), M.Sc. at the M-L University of Halle-Wittenberg (1999) and PhD in Solid-State Physics (2006) at Leipzig University, Germany. 17+ years of experience in the semiconductor industry (R&D), with focus on wafer-bonding process.
Naomi Vouillamoz
M.Sc. in Structural Geology at Neuchâtel University (2006), PhD in seismology/microtectonics at Fribourg University (2015), Switzerland. Five academic awards. FNS postdoc fellow at the Institute for Geophysics of Stuttgart University, Germany (2015-2018). 12+ years of experience in transversal and applied research projects using multi-disciplinary approaches.
Scientific and Medical Advisory Board
Daniel A. Rüfenacht
MD, PhD. Founder and Head of SwissNeuroInstitute, Hirslanden Clinic in Zurich. Co-founder of ESMINT (European Society of Minimally Invasive Neurological Therapies). Research devoted to development of image guided minimally invasive treatment concerning neurovascular diseases, tumors and back pain. Honorary Professor at Dept. of Cardiovascular Science, University of Sheffield, UK.
Alex Dommann
Prof. Dr. Head Dept. “Materials meet Life” at Empa. CTI expert for Micro- and Nanotechnology.
Adolfo Fucci
M.Sc. in Electronics. Honorary member of CERN. More than 40 years experience in electronics design of computer architectures, specialised processors, complex readout systems and real-time high-speed data acquisition in prestigious research centres (Olivetti/Italy and CERN). Contribution to technology transfer efforts from research centres to industry.
Osman Ratib
MD, PhD. Head of Nuclear Medicine and Molecular Imaging Division at University Hospital of Geneva. Director of the Institute of Translational Molecular Imaging. Professor Emeritus of Molecular and Medical Pharmacology at UCLA. President of the OsiriX foundation (Open-Source software).
Hans von Känel
Ph.D. in natural sciences at ETH Zürich in 1978; post-doctoral Associate at MIT in Cambridge, Massachusetts, USA, 1979 - 1981; senior researcher at ETH Zürich 1981-2002; ordinary professor of physics at the Politecnico di Milano 2002-2007; CTO of the start-ups Epispeed 2003-2010 and PileGrowth Tech 2012-2015; 400+ scientific publications in surface & interface physics, semiconductor physics, nanotechnology and epitaxial growth; 20 patent applications.
Ulrich Sigwart
MD, PhD. Professor and chair of Cardiology Emeritus, University of Geneva. Pioneer in the conception and clinical use of intravascular stents to prevent occlusion/restenosis after angioplasty and in the non-surgical treatment of hypertrophic obstructive cardiomyopathy.